Several of these mutations have been identified in patients with TRK fusion-positive cancers that have progressed on entrectinib [10, 24] or larotrectinib [20], indicating that these represent a shared liability for the first-generation TRK inhibitors. The gene discussed is NTRK1; the disease is cancer.